Shanghai - Delayed Quote CNY

InnoCare Pharma Limited (688428.SS)

26.44 +0.22 (+0.84%)

At close: 3:00:02 PM GMT+8

2026 ASH Oral Presentation | InnoCare Announces Phase III Results of Orelabrutinib in ITP Study Meet Primary Endpoint

GlobeNewswire 3d ago

688428.SS
+0.84%
9969.HK
InnoCare Announces First Subject Dosed in Clinical Trial of TL1A/IL-23p19 Bispecific Antibody ICP-B161 in China

GlobeNewswire 10d ago

688428.SS
+0.84%
9969.HK
InnoCare Pharma (SEHK:9969) Stock Shrugs Off Q3 Earnings Turnaround

Simply Wall St. 12d ago

688428.SS
+0.84%
9969.HK
InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization

GlobeNewswire 13d ago

688428.SS
+0.84%
LLY

9969.HK
$InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China$

InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China

GlobeNewswire 27d ago

688428.SS
+0.84%
9969.HK
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

GlobeNewswire 28d ago

688428.SS
+0.84%
9969.HK
Is InnoCare Pharma (SEHK:9969) Undervalued On Its Eli Lilly Deal?

Simply Wall St. 1mo ago

688428.SS
+0.84%
LLY

9969.HK
Eli Lilly and InnoCare sign drug discovery deal worth up to $3.35B

Quartz 1mo ago

688428.SS
+0.84%
LLY
Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare

Pharmaceutical Technology 1mo ago

688428.SS
+0.84%
LLY
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines

GlobeNewswire 1mo ago

688428.SS
+0.84%
LLY

9969.HK
InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China

GlobeNewswire 1mo ago

688428.SS
+0.84%
9969.HK
InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in China

GlobeNewswire 3mo ago

9969.HK

U.S. markets open in 4h 41m

InnoCare Pharma Limited (688428.SS)

2026 ASH Oral Presentation | InnoCare Announces Phase III Results of Orelabrutinib in ITP Study Meet Primary Endpoint

InnoCare Announces First Subject Dosed in Clinical Trial of TL1A/IL-23p19 Bispecific Antibody ICP-B161 in China

InnoCare Pharma (SEHK:9969) Stock Shrugs Off Q3 Earnings Turnaround

InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization

InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

Is InnoCare Pharma (SEHK:9969) Undervalued On Its Eli Lilly Deal?

Eli Lilly and InnoCare sign drug discovery deal worth up to $3.35B

Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare

InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines

InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China

InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in China